Orforglipron Improves Glucose Tolerance, Reduces Food Intake, and Lowers Adipose Tissue Weight in HFD-Induced Humanized GLP-1R Mice B-hGLP1R mice plus were fed a high-fat diet (HFD) to induce obesity, followed by Orforglipron treatment
semaglutide in reducing body weight among obese or overweight individuals, a benefit that was apparent regardless of the presence of type 2 diabetes, while the rates of gastrointestinal adverse events were similar between the two drugs [62]
The most common side effects of GLP-1 drugs are gastrointestinal, such as nausea, vomiting, and diarrhea
A full taper can take a few weeks to a few months
The drug is contraindicated during pregnancy [4]
Both supplements help in detoxifying the body and support antioxidant levels, with NAC being a precursor to glutathione production